{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T05:53:41Z","timestamp":1718690021844},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,4,15]]},"DOI":"10.2169\/internalmedicine.1846-23","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T22:57:17Z","timestamp":1693522637000},"page":"1113-1117","source":"Crossref","is-referenced-by-count":3,"title":["Thrombotic Microangiopathy after a 15-year Treatment with Interferon Beta-1b in a Patient with Multiple Sclerosis: A Case Report and Review of Literature"],"prefix":"10.2169","volume":"63","author":[{"given":"Satori","family":"Akita","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Fujibayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei-ichi","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Wakasa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Kajinami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Abou-Ismail MY, Kapoor S, Citla Sridhar D, Nayak L, Ahuja S. Thrombotic microangiopathies: an illustrated review. Res Pract Thromb Haemost 6: e12708, 2022.","DOI":"10.1002\/rth2.12708"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sukumar S, L\u00e4mmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med 10: 536, 2021.","DOI":"10.3390\/jcm10030536"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management. Front Pharmacol 13: 1088031, 2023.","DOI":"10.3389\/fphar.2022.1088031"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Palma LMP, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep 6: 11-23, 2021.","DOI":"10.1016\/j.ekir.2020.10.009"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Omoto S, Utsumi T, Matsuno H, Terasawa Y, Iguchi Y. Thrombotic microangiopathy presenting with intestinal involvement following long-term interferon-\u03b21b treatment for multiple sclerosis. Intern Med 57: 741-744, 2018.","DOI":"10.2169\/internalmedicine.9326-17"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Allinovi M, Cirami CL, Caroti L, et al. Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. Clin Kidney J 10: 625-631, 2017.","DOI":"10.1093\/ckj\/sfw143"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Parisi M, Manni A, Caputo F, Trojano M, Paolicelli D. A case report of late-onset atypical hemolytic uremic syndrome during interferon beta in multiple sclerosis: open issues in literature review. Brain Behav 11: e01930, 2021.","DOI":"10.1002\/brb3.1930"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vosoughi R, Marriott JJ. Thrombotic microangiopathy in interferon beta treated multiple sclerosis patients: review of literature and report of two new cases. Mult Scler Relat Disord 3: 321-325, 2014.","DOI":"10.1016\/j.msard.2013.12.007"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rogier T, Gerfaud-Valentin M, Pouteil-Noble C, et al. Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report. Rev Med Interne 37: 701-704, 2016.","DOI":"10.1016\/j.revmed.2015.12.027"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gianassi I, Allinovi M, Caroti L, Cirami CL. Broad spectrum of interferon-related nephropathies: glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy. A case report and review of literature. World J Nephrol 8: 109-117, 2019.","DOI":"10.5527\/wjn.v8.i7.109"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Allinovi M, Bellinvia A, Pesce F, et al. Safety and efficacy of eculizumab therapy in multiple sclerosis: a case series. Brain Sci 11: 1341, 2021.","DOI":"10.3390\/brainsci11101341"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mrabet S, Dahmane R, Raja B, et al. Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis. Br J Clin Pharmacol 89: 1682-1685, 2023.","DOI":"10.1111\/bcp.15631"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nerrant E, Charif M, Ramay AS, et al. Hemolytic uremic syndrome: an unusual complication of interferon-b treatment in a MS patient. J Neurol 260: 1915-1916, 2013.","DOI":"10.1007\/s00415-013-6961-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Broughton A, Cosyns JP, Jadoul M. Thrombotic microangiopathy induced by long-term interferon-b therapy for multiple sclerosis: a case report. Clin Nephrol 76: 396-400, 2011.","DOI":"10.5414\/CN106523"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mahe J, Meurette A, Moreau A, et al. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther 7: 723-728, 2013.","DOI":"10.2147\/DDDT.S42138"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Orvain C, Augusto JF, Besson V, et al. Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Int Urol Nephrol 46: 239-242, 2014.","DOI":"10.1007\/s11255-013-0401-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rubin S, Lacraz A, Galantine V, et al. Malignant hypertension and interferon-beta: a case report. J Hum Hypertens 28: 340-341, 2014.","DOI":"10.1038\/jhh.2013.91"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Larochelle C, Grand'maison F, Bernier GP, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon b. Mult Scler 20: 1783-1787, 2014.","DOI":"10.1177\/1352458514523692"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Calle IA, Menoyo JLS, Ojeda JR, et al. Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication? Neurologia 31: 508-509, 2016.","DOI":"10.1016\/j.nrleng.2014.09.005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Capobianco M, Piccoli G, Neve Vigotti F, et al. Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. Mult Scler 20: 889-891, 2014.","DOI":"10.1177\/1352458513519839"},{"key":"21","first-page":"79","volume":"4","author":"G Li Cavoli","year":"2011","unstructured":"21. Li Cavoli G, Bono L, Tortorici C, et al. Renal thrombotic microangiopathy induced by b-interferon. NDT Plus 4: 79-80, 2011.","journal-title":"NDT Plus","ISSN":"http:\/\/id.crossref.org\/issn\/1753-0784","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Olea T, D\u0131az-Mancebo R, Picazo ML, et al. Thrombotic microangiopathy associated with use of interferon-beta. Int J Nephrol Renovasc Dis 5: 97-100, 2012.","DOI":"10.2147\/IJNRD.S30194"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med 370: 1270-1271, 2014.","DOI":"10.1056\/NEJMc1316118"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Serrano A, Xicoy B, Grifols JR, et al. Thrombotic thrombocytopenic purpura during treatment with interpheron. Med Clin (Barc) 128: 276-277, 2007.","DOI":"10.1016\/S0025-7753(07)72559-9"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/8\/63_1846-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T03:30:50Z","timestamp":1713583850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/8\/63_1846-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1846-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"article-number":"1846-23"}}